Runben Biotechnology Co

Runben Biotechnology Co Forward P/E

The Forward P/E Ratio of Runben Biotechnology Co (603193.SS) as of Oct 16, 2026 is 26.60. In the previous year, Forward P/E Ratio was 27.87 — a change of -4.56% (lower).

Forward P/E

26.60

YoY

-4.56%

Last updated:

Forward P/E Ratio of Runben Biotechnology Co is 2025 26.60 . Forward P/E Ratio of Runben Biotechnology Co was 2024 27.87 . It decreases by -4.56% lower compared to the previous year.

The Runben Biotechnology Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
234.52 CNY
Jan 1, 2020
88.33 CNY
Jan 1, 2021
69.34 CNY
Jan 1, 2022
52.27 CNY
Jan 1, 2023
37.01 CNY
Jan 1, 2024
27.87 CNY
Jan 1, 2025
26.60 CNY
The Runben Biotechnology Co Forward P/E history
YEARForward P/EYoY
26.60-4.56%
27.87-24.70%
37.01-29.19%
52.27-24.62%
69.34-21.50%
88.33-62.34%
234.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co Ltd, trading under the ticker symbol 603193.SS and identified by ISIN CNE100006DK5, is a Chinese enterprise operating within the Consumer Staples sector, specifically in the consumer products industry. Headquartered in Guangzhou, Guangdong, the company has established itself as a specialized manufacturer and distributor of personal care items, with a notable focus on mosquito repellents and baby care solutions. As of the latest available data, the firm employs 917 full-time staff members who support its extensive research, development, manufacturing, and sales operations. Runben Biotechnology officially entered the public markets via an initial public offering on October 17, 2023, marking a significant milestone in its corporate development and providing greater visibility into its financial and operational strategies. The company’s product portfolio is strategically divided into three primary categories: mosquito repellent products, baby care products, and essential oil-based items. Among its best-selling offerings are electric mosquito repellent liquids and DEET-based repellent solutions, which cater to the growing consumer demand for effective and safe pest control measures. In the personal care segment, the firm produces a diverse range of skincare and hygiene products, including lipsticks, face creams, facial cleansers, and general skincare creams, targeting consumers who prioritize gentle and specialized formulations. The company’s business model relies heavily on digital commerce channels, utilizing internet sales platforms to reach its customer base directly. This includes online direct sales, distribution through major online platforms, and agency sales models that facilitate broader market penetration. By leveraging these e-commerce strategies, Runben Biotechnology has been able to maintain a strong presence in the domestic Chinese market, where the majority of its revenue is generated. The firm’s commitment to innovation in product formulation, combined with its agile distribution network, positions it as a competitive player in the crowded consumer goods landscape. Through its continued investment in research and development, the company aims to expand its product lines and enhance the quality of its offerings, ensuring it meets the evolving needs of modern consumers. The integration of traditional manufacturing expertise with modern digital sales tactics allows Runben Biotechnology to adapt quickly to market trends and maintain customer loyalty. As it continues to grow, the company remains focused on delivering high-quality, safe, and effective products that address everyday consumer concerns, particularly in the areas of personal hygiene and family care. Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Runben Biotechnology Co stock

Forward P/E Ratio of Runben Biotechnology Co is 26.60 in 2025.

Forward P/E Ratio of Runben Biotechnology Co changed from 27.87 to 26.60, representing a -4.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Runben Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co